Moreover, while traditional approaches use mice that have been genetically modified to produce human antibodies, these antibodies are not completely encoded by human genes and are, therefore, not ...

Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program.

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...

Discover how AAV-based gene therapy delivers anti-eosinophil antibodies, offering hope for chronic hypereosinophilia ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

“Our unique RenMice ® platform enables the discovery of fully human antibodies with high affinity, low immunogenicity, and favorable developability. With Adcendo’s extensive expertise in ...

GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

Data were summarized with the search of 'colorectal' and 'antibody' as of August 2012 at ClinicalTrials.gov [202]. EGFR: EGF receptor; mAb: Monoclonal antibody; VEGFR: VEGF receptor. The authors ...

Adcendo exercises its option to utilize Biocytogen’s fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need This collaboration further validates ...